| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.05 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.05 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.05 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.068 | 0.05 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.076 | 0.05 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.05 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.05 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.06 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.074 | 0.06 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.076 | 0.06 |